




UK Health
Security
Agency

UK Standards for Microbiology Investigations

Chlamydial zoonotic infections



Issued by the Standards Unit, UK Standards for Microbiology Investigations, UKHSA

Virology | V 57 | Issue no: 2.2 | Issue date: 23.05.25 | Page: 1 of 24

© Crown copyright 2025

Acknowledgments

UK Standards for Microbiology Investigations (UK SMIs) are developed under the auspices of UKHSA working in partnership with the partner organisations whose logos are displayed below and listed on [the UK SMI website](#). UK SMIs are developed, reviewed and revised by various working groups which are overseen by a [steering committee](#).

The contributions of many individuals in clinical, specialist and reference laboratories who have provided information and comments during the development of this document are acknowledged. We are grateful to the medical editors for editing the medical content.

UK SMIs are produced in association with:

Applied
Microbiology
International

Association for
Laboratory
Medicine

BIAM
British Infection Association

BRITISH SOCIETY FOR
ANTIMICROBIAL
CHEMOTHERAPY

BRITISH SOCIETY FOR
MEDICAL MYCOLOGY
BSM

BSMT
BRITISH SOCIETY FOR
MICROBIAL TECHNOLOGY

BRITISH SOCIETY FOR PARASITOLOGY
BSP

COINDEITHAS • FEICROBIOLOG • CYMRU
WMA

Healthcare
Infection
Society

HSC Public Health
Agency

IBMS Institute of
Biomedical Science

MICROBIOLOGY
SOCIETY

NHS
National
Services
Scotland

PATHNET NI
Pathology Network, Northern Ireland

Public Health
Scotland

GIG Iechyd Cyhoeddus
CYMRU Cymru
NHS Public Health
WALES Wales

RCGP Royal College of
General Practitioners

The Royal College of Pathologists
Pathology: the science behind the cure

SAM
Society for Anaerobic Microbiology

Scottish Microbiology
and Virology Network

**THE UK CLINICAL
VIROLOGY NETWORK**

UKAS
United Kingdom
Accreditation
Service

Displayed logos correct as of December 2024.

Contents

Acknowledgments	2
Contents	3
Amendment table	4
1 General information	7
2 Scientific information	7
3 Scope of document	7
4 Introduction	7
5 Technical information/limitations	13
6 Specimen transport, storage and retention	13
7 Public health management	14
8 Appendix 1: Taxonomy of Chlamydiales	15
9 Appendix 2: Diseases caused by Chlamydiae in man and in animals	16
10 Notification to UKHSA or equivalent in the devolved administrations	18
11 Public health responsibilities of diagnostic laboratories	18
References	20

Amendment table

Each UK SMI document has an individual record of amendments. The amendments are listed on this page. The amendment history is available from standards@ukhsa.gov.uk.

Any alterations to this document should be controlled in accordance with the local document control process.

Amendment number/date	6/23.05.25
Issue number discarded	2.2
Insert issue number	2.1
Section(s) involved	Amendment
Whole document.	<p>This is an administrative point change.</p> <p>The content of this UK SMI document has not changed.</p> <p>The last scientific and clinical review was conducted on 14/11/2014.</p> <p>Hyperlinks throughout document updated to Royal College of Pathologists website.</p> <p>Public Health England replaced with UK Health Security Agency throughout the document, including the updated Royal Coat of Arms</p> <p>Partner organisation logos updated.</p> <p>Broken links to devolved administrations replaced.</p> <p>References to NICE accreditation removed.</p> <p>Scope and Purpose replaced with General and Scientific information to align with current UK SMI template.</p>
Section 10: Public health responsibilities of diagnostic laboratories	This section has been added to UK SMI templates to highlight the public health responsibilities that diagnostic laboratories have as part of their duties.

Amendment number/date	5/27.10.16
Issue number discarded	2
Insert issue number	2.1

Anticipated next review date*	14.11.17
Section(s) involved	Amendment
Whole document.	V 57 formerly G 3. Document presented in a new format.

Amendment number/date	4/14.11.14
Issue number discarded	1.2
Insert issue number	2
Section(s) involved	Amendment
Whole document.	Hyperlinks updated to gov.uk.
Page 2.	Updated logos added.
Scope of document.	The type of specimens in this section of the text has been updated.
Introduction.	Taxonomy updated. More information has been added to the section. Some sentences were moved to other sections where it fits while some were reworded.
Avian chlamydiosis.	Updated to include information regarding molecular methods that could be used in diagnosis of chlamydial infections.
Diagnosis of psittacosis/ornithosis.	This section has been updated to include the molecular, culture and serology methods that could be used in diagnosis of psittacosis/ornithosis.
Zoonotic infection with chlamydiae of ruminant origin.	Updates have been done in section 3 and two more web links have also been updated. There is a mention of families Parachlamydiaceae and Waddliaceae being recognised as agents of adverse pregnancy outcomes.
Diagnosis of chlamydial abortion.	This section has been updated to include the molecular and serology methods that could be used in diagnosis of chlamydial abortion.
Reporting.	This section is a new addition to the document.
Appendix 1: Taxonomy of Chlamydiales.	This section has been developed for guidance.

Appendix 2: Diseases caused by chlamydiae in man and in animals.	This section has been developed for guidance.
References.	Some references updated.

1 General information

[View general information](#) related to UK SMIs.

2 Scientific information

[View scientific information](#) related to UK SMIs.

3 Scope of document

Type of specimen

Serum, plasma, whole blood, sputum, tracheal aspirate, pleural fluid, bronchoalveolar fluid, throat swabs, eye swabs, placental tissue from abortions, amniotic fluid, nasopharyngeal aspirates

This UK SMI describes zoonotic Chlamydial infections in humans only.

This UK SMI should be used in conjunction with other UK SMIs.

4 Introduction

Classification of the Gram negative bacteria within the order Chlamydiales has always been controversial. The order's taxonomy has now been revised and expanded^{1,2}, based on molecular biology and phylogenetic analysis of the 16S and 23S ribosomal RNA (rRNA) genes, and is supported by analyses of several other genes, including the major outer membrane protein gene (MOMP)^{2,3}. This revised taxonomy has been adopted by most researchers working on animal chlamydiosis but is still disputed by some involved in human infections¹.

The order Chlamydiales currently contains four families, namely Chlamydiaceae, Parachlamydiaceae, Simkaniaceae and Waddliaceae.

The family Chlamydiaceae contains two genera, *Chlamydia* and *Chlamydophila*, which are abbreviated as *C* and *Cp*¹. There are nine species within these genera: three for the genus *Chlamydia* (*Chlamydia trachomatis*, *Chlamydia muridarum*, and *Chlamydia suis*); and six for the genus *Chlamydophila* (*Chlamydophila pneumoniae*, *Chlamydophila pecorum*, *Chlamydophila psittaci*, *Chlamydophila abortus*, *Chlamydophila caviae* and *Chlamydophila felis*^{4,5}. The latter four species were known, collectively, as *Chlamydia psittaci* prior to taxonomic revision.

It is notable that, for all four of the new species that used to make up *Cp. psittaci*, the distinct tissue tropisms seen in the natural hosts are also observed in zoonotic infections. Understanding the cellular and molecular bases of these tropisms still constitutes a major challenge for future research.

Parachlamydiaceae has two genera, *Neochlamydia* and *Parachlamydia*, each with one species only (*Neochlamydia hartmanellae* and *Parachlamydia acanthamoebae* respectively).

The remaining families, Simkaniaceae and Waddliaceae, contain one species each (*Simkania nevegensis* and *Waddlia chondrophila* respectively).

Simkania nevegensis has been associated with human respiratory disease⁶. *Simkania* and the Parachlamydiaceae have been detected by polymerase chain reaction (PCR) in a wide range of clinical specimens from both human and animal sources. They are considered to be emerging pathogens but, as animal to human transmission has not been described, they are currently outside the scope of this document⁷⁻⁹.

Diagnosis of chlamydial infections has benefited greatly from the introduction of molecular techniques, particularly PCR. These have allowed the detection, identification and quantification of chlamydial infections, such as *Cp. psittaci* with relative ease^{10,11}. DNA microarrays or sequencing can also be used for diagnosis. Further analysis can also be done using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) or Multi-locus VNTR analysis (MLVA)¹².

Alternative tests for diagnosis of avian chlamydiosis include culture, immunohistochemical staining, serology assays such as enzyme-linked immunosorbent assay (ELISA), Indirect fluorescent antibody (IFA), microimmunofluorescence test (MIF) and Complement Fixation Test (CFT)^{13,14}. However, some cross reactivity with other Chlamydiae including *Cp. pneumoniae*, *C. trachomatis*, and *Cp. felis* can occur in all serological tests¹⁵.

Diagnostic testing for chlamydial zoonoses is unsatisfactory. There are no commercially available test procedures, in either human or veterinary medicine, which are both sensitive and species-specific. Species-specific testing is largely restricted to specialised laboratories¹⁶.

This document will describe the two well established types of zoonotic chlamydial infection, including their diagnosis and briefly review the surveillance that may be needed in the future.

4.1 Avian chlamydiosis

Avian chlamydiosis is caused by the *Chlamydophila psittaci*. *Cp. psittaci* has at least eight serovars (six avian serovars and two mammalian isolates and nine genotypes (seven avian and two non-avian genotypes based on *ompA* sequence variations). Chlamydial infections from birds were among the earliest recognised zoonotic infections but, even so, several publications suggest that the spectrum of diseases caused by such chlamydial infections may be much wider than was realised before^{9,17}.

Avian chlamydiosis was previously named psittacosis, or parrot fever, as the disease was originally recognised to originate from psittacine birds. Although the condition was first described in the 19th century the fashion for avian pets, particularly parrots, in the 1930s led to many cases of psittacosis and greatly raised public awareness of the disease. In 1941 the term “ornithosis” was introduced to refer to chlamydial disease in, or contracted from, domestic poultry and other non-psittacine birds^{18,19}. These diseases in birds are now all considered to be similar, and the term avian chlamydiosis is preferred. ‘Psittacosis’ still tends to be used to describe the disease in humans.

Cp. psittaci is found in the faeces, respiratory secretions and feather dust of infected birds and therefore direct contact with an infected bird is not necessary for infection. Transmission of disease occurs mainly through inhalation of aerosols, respiratory secretions, or dried faecal or feather dust, but oral infection (mouth-to-beak contact) and handling of plumage and tissues are alternative routes. The incubation period is 5-15 days. In serious cases the disease progresses from flu-like symptoms, through pneumonia to acute respiratory failure and septic shock. Many other symptoms and signs have been reported²⁰. In the pre-antibiotic era, mortality was estimated at 15-20% of reported infections²¹.

Major outbreaks among poultry have occurred on turkey and duck farms and have often led to infection of humans. A few outbreaks have also been reported in farmed geese. Although chickens appear to be more resistant, natural infections have been reported in breeder flocks, broilers and layers. In humans, chlamydial infections usually result from exposure to infected pet psittacine birds such as cockatiels, parakeets, parrots, budgerigars and macaws; however, human infections have also often been linked to non-psittacine pet birds (finches, canaries, pigeons, doves and mynah birds)¹⁰. Outbreaks have also occurred in humans following slaughter and processing of infected ducks and turkeys¹². Transmission from human to human is rare but has been reported in an outbreak of psittacosis in Scotland in 2012²². Transmission from humans to birds has not been documented^{22,23}.

4.2 Diagnosis of psittacosis/ornithosis

All current laboratory tests for avian chlamydiosis have drawbacks and the need for better means of diagnosis has been recognised for many years²⁴. For this reason early diagnosis and treatment based on history and clinical signs, is recommended rather than waiting for laboratory results.

Early diagnosis and treatment may well depend on obtaining a history of contact with birds, or an environment contaminated by birds, and giving anti-chlamydial antibiotics on grounds of suspicion. An early review of psittacosis cases in Cambridgeshire from 1975-83 (prior to the identification of *Cp. pneumoniae*) found bird contact in only 17% of cases²⁵. However a later review of cases in the same county, in which *Cp. pneumoniae* and *Cp. psittaci* infections were differentiated by the micro-immunofluorescence test (MIF, see below), reported that bird contact could be established in 84% of confirmed cases²⁶.

Note: Extreme care must be exercised with respiratory samples as *Cp. psittaci* is a category three pathogen.

Molecular methods

PCR allows the detection, identification and quantification of chlamydial infections with relative ease. The stability of molecular reagents and control material also make this rapid method very suitable for sporadic or infrequent testing^{7,10,27}.

Other rapid molecular techniques that are available in specialised reference laboratories are DNA micro-arrays, PCR-RFLP and *ompA* gene sequencing (for differentiation of the two closely related species *Cp. psittaci* and *Cp. abortus*)^{14,16,28-31}.

Serology

Historically, serology has been the mainstay of a diagnosis. Serum should be tested in parallel and a definitive diagnosis depends on observing a fourfold (or greater) rise in

antibody titre, which may take 2-4 weeks to develop. This may be helpful when used retrospectively or for epidemiological purposes in outbreak situations. However for individual patients, serology gives only a delayed answer at best and obtaining paired sera can be difficult.

Frequently used serological tests for *Cp. psittaci* diagnosis in humans are CFT, ELISA and MIF.

The CFT is the traditional test, though it is now unavailable in many laboratories. The test detects antibodies to epitopes of chlamydial lipopolysaccharides (LPS) which are present in all members of the Chlamydiaceae, thus a positive result may be due to infection with *Cp. pneumoniae* or *C. trachomatis*.

The current reference standard is the MIF test, which was originally developed by Wang and Grayston for serotyping of *C. trachomatis*³². This test is more sensitive and specific than the CFT³³. MIF uses elementary bodies (EBs) of the three human chlamydial pathogens, fixed microscope slides as antigen for detecting both total immunoglobulin and specific IgM or IgA. As EBs are at the limits of light microscope resolution, endpoint detection can be difficult and the test suffers from considerable inter-operator variability³⁴. The main antigen presented in the MIF test is MOMP and this is known to be highly variable in avian isolates, with 8 serovars currently described¹⁴. Thus the infecting strain may well be different from that used to produce the elementary bodies for the test, resulting in a false negative result.

As some of the outer chlamydial antigens, such as LPS, can cross-react with antibodies to other bacteria, positive results from either MIF or CFT must be interpreted cautiously^{15,21,35}. MIF tests and ELISAs using chlamydial antigens with reduced LPS have now been developed. However, due to serological cross-reaction between different species of the Chlamydiaceae family, it remains difficult to distinguish *Cp. psittaci*, *C. trachomatis* and *Cp. pneumoniae* antibodies in any of the current serological tests.

An alternative to the MIF test is the whole inclusion immunofluorescence test (WIF) that tests sera against slides bearing *C. trachomatis*, *Cp. pneumoniae* and *Cp. abortus* infected cells³⁶. *Cp. Abortus* (see section 3, below) is used in preference to *Cp. psittaci* since it is known to be very closely antigenically related to *Cp. psittaci* and this avoids the biohazard of growing *Cp. psittaci* which is a Category 3 pathogen. WIF is much easier to read than MIF and is the only test that presents all the chlamydial antigens including the 'non-structural' antigens present in the inclusion membranes. This is both an advantage and a disadvantage. It increases sensitivity but decreases specificity due to cross-reactions, especially those due to anti-LPS antibodies that react with all three species³⁷. As a result, sera that show equivalent titres to *Cp. pneumoniae* and *Cp. psittaci* in the WIF test are considered to be infections with the latter, largely on grounds of clinical prudence.

Serological diagnosis of *Cp. psittaci* and *Cp. abortus* infections would be greatly simplified and accelerated if a specific immunodominant antigen or antigens for these species could be found. Two novel forms of LPS oligosaccharide found only in *Cp. psittaci* /*abortus* /*felis* /*caviae*, have been described and may well provide such antigens³⁸. A monoclonal antibody against this novel LPS was found to be specific, but does not yet form the basis of any commercially available test.

Antigen detection

A more timely diagnosis would be achieved by direct pathogen detection in sputum, throat swabs or respiratory aspirates.

Antigen ELISA tests for *Cp. psittaci* or *Cp. abortus* in human medicine are not commercially available at present. However, if antigen ELISAs are to be used for detecting all the species of *Chlamydophila*, users should bear in mind that these tests are inferior to both detection in culture and the PCR with respect to sensitivity and specificity and that this can often at times, lead to misinterpretation of results^{16,23}.

Culture

Isolation of the organism by culture is the most reliable method to prove the presence of viable bacteria in a human (or avian) case of psittacosis. Diagnosis by culture can only be performed in a limited number of laboratories because of the need for a Containment Level 3 facility.

The isolation of *Cp. psittaci* is normally performed in cell cultures, often in the presence of cycloheximide. The use of numerous cell types has been described, including Buffalo Green Monkey (BGM), McCoy, HeLa, African Green Monkey (Vero) and L-929 cells, with BGM cells shown to offer the best yield. The presence of *Cp. psittaci* is usually confirmed by immunofluorescence, immunoperoxidase staining or other similar techniques. Isolates can be serotyped with monoclonal antibodies, or genotyped with real-time PCR, DNA microarrays or DNA sequencing.

Cp. pneumoniae is more difficult to grow than other species but isolation rates are better in HeLa cells than in McCoy cells.

4.3 Zoonotic infection with chlamydiae of ruminant origin

Cp. abortus is the main cause of infectious abortion in sheep and goats in the UK and also cause occasional abortions in cattle. Recent evidence from the USA has suggested that low grade infection in cattle is widespread and may be responsible for fertility problems³⁹. In sheep, the main pathology is found in the placenta but the fetus is also infected¹⁷. When sheep abort, there is usually massive excretion of chlamydiae in the infected placenta and on the aborted lamb which is a source of infection for other sheep and humans.

The infection in men and non-pregnant women is not well documented but an outbreak among workers preparing vaccine in 1981 suggested that it causes a relatively mild upper respiratory tract infection with influenza-like symptoms such as headache, chills, fever, joint pains and non-productive cough. Photophobia, vomiting, sore throat and myocarditis may also occur⁴⁰.

If pregnant women become infected, the infection can spread to the placenta following the respiratory symptoms and may result in abortion or stillbirth. Severe symptoms including renal failure, hepatic dysfunction and disseminated intravascular coagulation can occur around the time of fetal loss and may lead to the death of the mother in extreme cases^{17,41}. If the pregnancy survives the acute infection, there is no evidence that *Cp. abortus* causes congenital malformation or any risk to subsequent pregnancies.

The risk is limited mainly to those actively working with sheep, including veterinary surgeons, and their immediate families⁴². The route of transmission to humans is not

known for certain, however inhalation of aerosols and dusts heavily contaminated with *Cp. abortus* appears to be the likely route of infection. Contact with aborting sheep or sheep at risk of abortion, dead lambs and placentae are thus considered to represent a risk for humans. When lambing and handling of pregnant and post-partum ewes takes place indoors, the risk of human exposure to the organism may be greater than in open pastures. Infection has also been associated with handling of contaminated clothing and boots and contact with birds may be a risk⁴².

Clearly for this infection, prevention is the best policy. Following recognition of the problem during the 1980s and 1990s, the dangers received considerable publicity in the farming and general press and, most effectively, in the agricultural soap operas. Currently, detailed advice for women who might be at risk is available from UKHSA (<https://www.gov.uk/poultry-health>), DEFRA (<http://webarchive.nationalarchives.gov.uk/20130402151656/http://archive.defra.gov.uk/foodfarm/farmanimal/diseases/atoz/zoonoses/lambing.htm>) and the HSE (www.hse.gov.uk).

That *Cp. abortus* is indeed the chlamydial species involved was established by whole genome restriction enzyme profiling (WGREP)⁴³.

There is now growing evidence that Parachlamydiaceae are also associated with adverse pregnancy outcomes. *Parachlamydia* may represent an agent of miscarriage in humans^{44,45}. *Waddlia*, a *Chlamydia*-like organism first isolated from an aborted bovine, has emerged as an agent of abortion in cattle and more recently was implicated in human fetal death⁴⁵. Achieving a better definition of the role of *Chlamydia* species and confirming the roles of other *Chlamydia*-like organisms in human miscarriage, stillbirth and preterm labour are major research challenges for the future.

4.4 Diagnosis of chlamydial abortion

Diagnosis of *Cp. abortus* in a person with positive serology for chlamydial infection is dependent primarily on clinical and epidemiological suspicion. It is important to establish diagnosis quickly in order to start aggressive anti-chlamydial therapy as soon as possible. Direct detection of the pathogen in aborted placenta and/or fetus is the quickest method of making a diagnosis.

The WIF test uses *Cp. abortus* antigen and so is particularly suitable for specific serological diagnosis of *Cp. abortus* infection although historically the CFT has been used in most cases. CFT however, does not distinguish between different species of *Chlamydophila*. Antigen ELISA tests for *Cp. abortus* are currently not commercially available.

Isolation in cell culture is extremely difficult for some species and so is restricted to very few laboratories with extensive practical experience¹⁶. However, the introduction of molecular methods, such as PCR, DNA microarrays, multi-locus sequence typing (MLST) and *ompA* gene sequencing, has allowed the detection, identification and quantification of chlamydial infections with relative ease without the need for culture^{14,16,28-30}.

Further research is still required to define the zoonotic potential of *Cp. abortus* of avian origin, as well as *Cp. psittaci* from non-avian sources.

Note: Additional diagnostic testing may be available from the Veterinary Laboratories Agency and the Moredun Research Institute, Edinburgh.

4.5 Reporting

Human psittacosis is a notifiable disease in some European countries (Germany, Denmark) but is not in the UK. However, the organism *Cp. psittaci* is listed as notifiable in the Public Health Scotland Act of 2008 and Health Protection Legislation (England) Guidance 2010^{46,47}.

A case may be suspected when the request bears relevant information, for example:

- abortion or stillbirth with maternal renal failure, hepatic dysfunction and disseminated intravascular coagulation
- clinically consistent illness after occupational or domestic exposure to birds or ruminants (see Appendix 2)
- investigation of possible outbreaks associated with bird and animal farms

Follow local protocols for reporting all presumptive and confirmed infections to the patients' clinicians.

5 Technical information/limitations

5.1 Limitations of UK SMIs

The recommendations made in UK SMIs are based on evidence (for example, sensitivity and specificity) where available, expert opinion and pragmatism, with consideration also being given to available resources. Laboratories should take account of local requirements and undertake additional investigations where appropriate. Prior to use, laboratories should ensure that all commercial and in-house tests have been validated and are fit for purpose.

5.2 Specimen containers^{48,49}

UK SMIs use the term “CE marked leak proof container” to describe containers bearing the CE marking used for the collection and transport of clinical specimens. The requirements for specimen containers are given in the EU in vitro Diagnostic Medical Devices Directive (98/79/EC Annex 1 B 2.1) which states: “The design must allow easy handling and, where necessary, reduce as far as possible contamination of and leakage from, the device during use and, in the case of specimen receptacles, the risk of contamination of the specimen. The manufacturing processes must be appropriate for these purposes”.

6 Specimen transport, storage and retention^{48,49}

6.1 Optimal transport and storage conditions

Specimens should be transported and processed as soon as possible⁵⁰.

Samples should be retained in accordance with The Royal College of Pathologists guidelines 'The retention and storage of pathological records and specimens'⁵¹.

7 Public health management

For information regarding notification to UKHSA (or equivalent in the devolved administrations) refer to the section on 'Notification to UKHSA or equivalent in the devolved administrations' at the end of this document.

8 Appendix 1: Taxonomy of Chlamydiales

Domain	Bacteria					
Class	Chlamydiae					
Order	Chlamydiales					
Family	Chlamydiaceae		Parachlamydiaceae		Simkaniaceae	Waddliaceae
Genera	<i>Chlamydia</i>	<i>Chlamydophila</i>	<i>Neochlamydia</i>	<i>Parachlamydia</i>	<i>Simkania</i>	<i>Waddlia</i>
Species	<i>C. muridarum</i> <i>C. suis</i> <i>C. trachomatis</i>	<i>Cp. abortus</i> <i>Cp. caviae</i> <i>Cp. felis</i> <i>Cp. pecorum</i> <i>Cp. pneumoniae</i> <i>Cp. psittaci</i>	<i>Neochlamydia</i> <i>hartmanellae</i>	<i>Parachlamydia</i> <i>acanthamoebae</i>	<i>Simkania</i> <i>nevegensis</i>	<i>Waddlia</i> <i>chondrophila</i>

Adapted and compiled from current journals¹⁻⁵.

9 Appendix 2: Diseases caused by Chlamydiae in man and in animals

Genus	Host		Pathology in animals		Route for human transmission	Pathology in humans	
	Principal	Occasional	Common signs	Severe disease		Common signs	Uncommon / severe disease
Chlamydophila species							
Cp. psittaci	Birds (parrots, domestic poultry)	Dogs, horses, pigs	Hyperthermia , anorexia, lethargy, diarrhoea	Conjunctivitis pneumonia, pericarditis, death	Inhalation	Influenza-like illness	Endocarditis, encephalitis, pneumonia, death
Cp. abortus	Ruminants (sheep, goats cattle)	Pigs, deer, horses, rabbits, koalas, guinea pigs, mice	Abortion, stillbirth, epididymitis	Endometritis	Inhalation	Influenza-like illness	Pneumonia, abortion, renal failure, respiratory distress, death
Cp. felis	Cats	–	Conjunctivitis	Pneumonia, chronic salpingitis	Direct contact	Conjunctivitis	Endocarditis, liver failure
Cp. caviae	Guinea-pigs	–	Conjunctivitis , genital tract infection	–	Direct contact	Conjunctivitis	–
Cp. pneumoniae	Humans, koalas, horses	Reptiles and amphibians	Respiratory diseases	–	Fomites Inhalation	Pneumonia, Bronchitis, Asthma	Atherosclerosis Reactive arthritis
Cp. pecorum	Ruminants (cattle, sheep and goats), pigs,	koalas	Intestinal infection, abortion, conjunctivitis, urinary tract disease	Encephalomyelitis, pneumonia, arthritis	Direct contact	Non-pathogenic in man	
Chlamydia species							
C. muridarum	Mice	-	-	-	-	Non-pathogenic in man	
C. suis	Pigs	-	Pneumonia, enteritis, conjunctivitis (pig)	-	-	Non-pathogenic in man	

Chlamydial zoonotic infections

<i>C. trachomatis</i>	Humans	-	Unknown	Unknown	Direct contact Fomites Inhalation	Urogenital infection Adnexitis Conjunctivitis Trachoma Venereal lymphogranuloma	Reactive arthritis Neonatal pneumonia
<i>Simkania negevensis</i>	Unknown	humans	Unknown	Unknown	Inhalation	Respiratory infections	
<i>Parachlamydia acanthamoebae</i>	Acanthamoeba	Goats, sheep,	Pneumonia, abortion	-	? Inhalation	Emerging role as an agent of bronchiolitis, pneumonia, miscarriage in humans	
<i>Waddlia chondrophila</i>	Cattle	-	Abortion	Unknown	? Contact with pets, through uncooked meat and milk	May be associated with miscarriages in humans.	

Adapted from current journals^{1,8,9,16,44,45,52-54}.

10 Notification to UKHSA^{47,55}, or equivalent in the devolved administrations^{46,56-58}

The Health Protection (Notification) regulations 2010 require diagnostic laboratories to notify UK Health Security Agency (UKHSA) when they identify the causative agents that are listed in Schedule 2 of the Regulations. Notifications must be provided in writing, on paper or electronically, within seven days. Urgent cases should be notified orally and as soon as possible, recommended within 24 hours. These should be followed up by written notification within seven days.

For the purposes of the Notification Regulations, the recipient of laboratory notifications is the local UKHSA Health Protection Team. If a case has already been notified by a registered medical practitioner, the diagnostic laboratory is still required to notify the case if they identify any evidence of an infection caused by a notifiable causative agent.

Notification under the Health Protection (Notification) Regulations 2010 does not replace voluntary reporting to UKHSA. The vast majority of NHS laboratories voluntarily report a wide range of laboratory diagnoses of causative agents to UKHSA and many UKHSA Health Protection Teams have agreements with local laboratories for urgent reporting of some infections. This should continue.

Note: The Health Protection Legislation Guidance (2010) includes reporting of Human Immunodeficiency Virus (HIV) & Sexually Transmitted Infections (STIs), Healthcare Associated Infections (HCAIs) and Creutzfeldt–Jakob disease (CJD) under ‘Notification Duties of Registered Medical Practitioners’: it is not noted under ‘Notification Duties of Diagnostic Laboratories’.

[Specialist and reference microbiology: laboratory tests and services - GOV.UK](#)

Other arrangements exist in [Scotland](#)^{46,56}, [Wales](#)⁵⁷ and [Northern Ireland](#)⁵⁸.

11 Public health responsibilities of diagnostic laboratories

Diagnostic laboratories have public health responsibility as part of their duties. Amongst these are additional local testing, or referral to further characterise the organism as required, primarily for public health purposes e.g. routine cryptosporidium detection; serotyping or microbial subtyping; and a duty to refer appropriate specimens and isolates of public health importance to a reference laboratory.

Diagnostic laboratory outputs inform public health intervention, and surveillance data is required to develop policy and guidance forming an essential component of healthcare. It is recognised that additional testing and referral of samples may entail some costs that has to be borne by the laboratory but in certain jurisdictions these costs are covered centrally.

Chlamydial zoonotic infections

Diagnostic laboratories should be mindful of the impact of laboratory investigations on public health and consider requests from the reference laboratories for specimen referral or enhanced information.

References

An explanation of the reference assessment used is available in the [scientific information](#).

1. Rodolakis A, Yousef MK. Zoonotic potential of Chlamydophila. VetMicrobiol 2010;140:382-91.
2. Everett KD, Bush RM, Andersen AA. Emended description of the order Chlamydiales, proposal of Parachlamydiaceae fam. nov. and Simkaniaceae fam. nov., each containing one monotypic genus, revised taxonomy of the family Chlamydiaceae, including a new genus and five new species, and standards for the identification of organisms. IntJ SystBacteriol 1999;49 Pt 2:415-40.
3. Bush RM, Everett KD. Molecular evolution of the Chlamydiaceae. IntJ SystEvolMicrobiol 2001;51:203-20.
4. Euzéby JP. List of Prokaryotic names with standing in nomenclature - Genus *Chlamydia*. 2014.
5. Euzéby JP. List of Prokaryotic names with standing in nomenclature - Genus *Chlamydophila*. 2014.
6. Friedman MG, Kahane S, Dvoskin B, Hartley JW. Detection of Simkania negevensis by culture, PCR, and serology in respiratory tract infection in Cornwall, UK. J Clin Pathol 2006;59:331-3.
7. Corsaro D, Greub G. Pathogenic potential of novel Chlamydiae and diagnostic approaches to infections due to these obligate intracellular bacteria. Clin Microbiol Rev 2006;19:283-97.
8. Greub G. Parachlamydia acanthamoebae, an emerging agent of pneumonia. ClinMicrobiolInfect 2009;15:18-28.
9. Wheelhouse N, Longbottom D. Endemic and emerging chlamydial infections of animals and their zoonotic implications. TransboundEmergDis 2012;59:283-91.
10. Heddema ER, van Hannen EJ, Duim B, de Jongh BM, Kaan JA, van Kessel R et al. An outbreak of psittacosis due to Chlamydophila psittaci genotype A in a veterinary teaching hospital. J Med Microbiol 2006;55:1571-5.
11. Heddema ER, Beld MG, de Wever B, Langerak AA, Pannekoek Y, Duim B. Development of an internally controlled real-time PCR assay for detection of Chlamydophila psittaci in the LightCycler 2.0 system. Clin Microbiol Infect 2006;12:571-5.

12. Laroucau K, de BB, Vorimore F, Clerc M, Bertin C, Harkinezhad T et al. Chlamydial infections in duck farms associated with human cases of psittacosis in France. *VetMicrobiol* 2009;135:82-9.
13. Chahota R, Ogawa H, Mitsuhashi Y, Ohya K, Yamaguchi T, Fukushi H. Genetic diversity and epizootiology of *Chlamydophila psittaci* prevalent among the captive and feral avian species based on VD2 region of ompA gene. *Microbiol Immunol* 2006;50:663-78.
14. Geens T, Desplanques A, Van Loock M, Bonner BM, Kaleta EF, Magnino S et al. Sequencing of the *Chlamydophila psittaci* ompA gene reveals a new genotype, E/B, and the need for a rapid discriminatory genotyping method. *J Clin Microbiol* 2005;43:2456-61.
15. Beeckman DS, Vanrompay DC. Zoonotic *Chlamydophila psittaci* infections from a clinical perspective. *ClinMicrobiolInfect* 2009;15:11-7.
16. Rohde G, Straube E, Essig A, Reinhold P, Sachse K. Chlamydial zoonoses. *DtschArzteblInt* 2010;107:174-80.
17. Longbottom D, Coulter LJ. Animal chlamydioses and zoonotic implications. *J Comp Pathol* 2003;128:217-44.
18. Anderson DC, Stoesz PA, Kaufmann AF. Psittacosis outbreak in employees of a turkey-processing plant. *AmJ Epidemiol* 1978;107:140-8.
19. Chalmers W. Duck ornithosis and related zoonosis in the UK. In: Oriel D, Ridgway GL, Schachter J, Taylor-Robinson D, Ward ME, editors. *Chlamydial Infections*: Cambridge University Press; 1986. p. 345-8.
20. Crosse BA. Psittacosis: a clinical review. *J Infect* 1990;21:251-9.
21. Bourke SJ, Carrington D, Frew CE, Stevenson RD, Banham SW. Serological cross-reactivity among chlamydial strains in a family outbreak of psittacosis. *J Infect* 1989;19:41-5.
22. McGuigan CC, McIntyre PG, Templeton K. Psittacosis outbreak in Tayside, Scotland, December 2011 to February 2012. *EuroSurveill* 2012;17.
23. European Commission. Avian Chlamydiosis as a zoonotic disease and risk reduction strategies. 2002.
24. Wreghitt T. Chlamydial infection of the respiratory tract. *CommunDis RepCDR Rev* 1993;3:R119-R24.
25. Nagington J. Psittacosis/ornithosis in Cambridgeshire 1975-1983. *J Hyg(Lond)* 1984;92:9-19.

26. Wreghitt TG, Barker CE, Treharne JD, Phipps JM, Robinson V, Buttery RB. A study of human respiratory tract chlamydial infections in Cambridgeshire 1986-88. *Epidemiol Infect* 1990;104:479-88.
27. Tong CY, Sillis M. Detection of *Chlamydia pneumoniae* and *Chlamydia psittaci* in sputum samples by PCR. *J Clin Pathol* 1993;46:313-7.
28. Pantchev A, Sting R, Bauerfeind R, Tyczka J, Sachse K. New real-time PCR tests for species-specific detection of *Chlamydophila psittaci* and *Chlamydophila abortus* from tissue samples. *VetJ* 2009;181:145-50.
29. Sachse K, Vretou E, Livingstone M, Borel N, Pospischil A, Longbottom D. Recent developments in the laboratory diagnosis of chlamydial infections. *VetMicrobiol* 2009;135:2-21.
30. Geens T, Dewitte A, Boon N, Vanrompay D. Development of a *Chlamydophila psittaci* species-specific and genotype-specific real-time PCR. *VetRes* 2005;36:787-97.
31. Sachse K, Laroucau K, Hotzel H, Schubert E, Ehricht R, Slickers P. Genotyping of *Chlamydophila psittaci* using a new DNA microarray assay based on sequence analysis of *ompA* genes. *BMCMicrobiol* 2008;8:63.
32. Wang SP, Grayston JT. Human serology in *Chlamydia trachomatis* infection with microimmunofluorescence. *J Infect Dis* 1974;130:388-97.
33. Smith KA, Campbell CT, Murphy J, Stobierski MG, Tengelsen AL. Compendium of Measures To Control *Chlamydophila psittaci* Infection Among Humans (Psittacosis) and Pet Birds (Avian Chlamydiosis), 2010 National Association of State Public Health Veterinarians (NASPHV). 2014.
34. Peeling RW, Wang SP, Grayston JT, Blasi F, Boman J, Clad A et al. *Chlamydia pneumoniae* serology: interlaboratory variation in microimmunofluorescence assay results. *J Infect Dis* 2000;181 Suppl 3:S426-S9.
35. Haralambieva I, Iankov I, Petrov D, Ivanova R, Kamarinchev.B., Mitov I. Cross-reaction between the genus-specific lipopolysaccharide antigen of *Chlamydia spp.* and the lipopolysaccharides of *Porphyromonas gingivalis*, *Escherichia coli* 0119 and *Salmonella newington*: Implications for diagnosis. *Diagnostic Microbiology and Infectious Disease* 2001;41:99-106.
36. Richmond SJ, Caul EO. Fluorescent antibody studies in chlamydial infections. *J Clin Microbiol* 1975;1:345-52.
37. Forsey T, Stainsby K, Hoger PH, Ridgway GL, Darougar S, Fischer-Brugge U. Comparison of two immunofluorescence tests for detecting antibodies to *C. trachomatis*. *EurJ Epidemiol* 1986;2:163-4.
38. Muller-Loennies S, Gronow S, Brade L, MacKenzie R, Kosma P, Brade H. A monoclonal antibody against a carbohydrate epitope in lipopolysaccharide

differentiates *Chlamydophila psittaci* from *Chlamydophila pecorum*, *Chlamydophila pneumoniae*, and *Chlamydia trachomatis*. *Glycobiology* 2006;16:184-96.

39. DeGraves FJ, Gao D, Hehnen HR, Schlapp T, Kaltenboeck B. Quantitative detection of *Chlamydia psittaci* and *C. pecorum* by high-sensitivity real-time PCR reveals high prevalence of vaginal infection in cattle. *J Clin Microbiol* 2003;41:1726-9.
40. Baker CC, Cooper B. A case of good management. *J Infect* 1983;6:71-3.
41. Buxton D. Potential danger to pregnant women of *Chlamydia psittaci* from sheep. *VetRec* 1986;118:510-1.
42. Caul EO, Roome AP, McGivern. Spontaneous abortion caused by *Chlamydia psittaci* of ovine origin. *CDR Weekly* 1986.
43. Herring AJ, Anderson IE, McClenaghan M, Inglis NF, Williams H, Matheson BA et al. Restriction endonuclease analysis of DNA from two isolates of *Chlamydia psittaci* obtained from human abortions. *BrMed J (Clin ResEd)* 1987;295:1239.
44. Blumer S, Greub G, Waldvogel A, Hassig M, Thoma R, Tschuor A et al. Waddlia, Parachlamydia and Chlamydiaceae in bovine abortion. *VetMicrobiol* 2011;152:385-93.
45. Baud D, Regan L, Greub G. Emerging role of *Chlamydia* and *Chlamydia*-like organisms in adverse pregnancy outcomes. *CurrOpinInfectDis* 2008;21:70-6.
46. Scottish Government. Public Health (Scotland) Act. 2008.
47. Department of Health. Health Protection Legislation (England) Guidance. 1-112. 2010.
48. European Parliament. UK Standards for Microbiology Investigations (UK SMIs) use the term "CE marked leak proof container" to describe containers bearing the CE marking used for the collection and transport of clinical specimens. The requirements for specimen containers are given in the EU *in vitro* Diagnostic Medical Devices Directive (98/79/EC Annex 1 B 2.1) which states: "The design must allow easy handling and, where necessary, reduce as far as possible contamination of, and leakage from, the device during use and, in the case of specimen receptacles, the risk of contamination of the specimen. The manufacturing processes must be appropriate for these purposes". 1998.
49. Official Journal of the European Communities. Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on *in vitro* diagnostic medical devices 1998. 1-37.
50. Baron EJ, Miller JM, Weinstein MP, Richter SS, Gilligan PH, Thomson RB, Jr. et al. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2013 Recommendations by the Infectious Diseases

Society of America (IDSA) and the American Society for Microbiology (ASM). ClinInfectDis 2013;57:e22-e121.

51. The Royal College of Pathologists. The retention and storage of pathological records and specimens (5th edition). 1-59. 2015.
52. Baud D, Thomas V, Arafa A, Regan L, Greub G. Waddlia chondrophila, a potential agent of human fetal death. EmergInfectDis 2007;13:1239-43.
53. Borel N, Pospischil A, Greub G. *Parachlamydia acanthamoebae* and Its Zoonotic Risk. Clinical Microbiology Newsletter 2010;32:185-91.
54. Ruhl S, Goy G, Casson N, Thoma R, Pospischil A, Greub G et al. Parachlamydia acanthamoebae infection and abortion in small ruminants. EmergInfectDis 2008;14:1966-8.
55. Public Health England. Laboratory Reporting to Public Health England: A Guide for Diagnostic Laboratories 2013. 1-37.
56. Scottish Government. Public Health etc. (Scotland) Act 2008. Implementation of Part 2: Notifiable Diseases, Organisms and Health Risk States. 2009.
57. The Welsh Assembly Government. Health Protection Legislation (Wales) Guidance. 2010.
58. Home Office. Public Health Act (Northern Ireland) 1967 Chapter 36. 1967.